14 usefulness of resistive index on spectral doppler ultrasonography in the detection of renal cell carcinoma in patients with end-stage renal disease

15 epidemiología del cáncer de tiroides.

16 Vacuole sign in roentgen diagnosis of early peripheral bronchogenic adenocarcinoma

17 [Immunopathological factors influencing the prognosis after resection of lung cancer]

18 [Therapeutic results after resection of asymptomatic lung cancer]

19 [Thorotrast infection into the maxillary sinus: appearance of a malpighien epithelioma 15 years later]

20 Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study

21 PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas

22 Saccharomyces cerevisiae fungemia in a head and neck cancer patient: a case report and review of the literature

23 Cabozantinib: An evolving therapy for hepatocellular carcinoma

24 Natural history of potentially malignant oral lesions and conditions: an overview of the literature

25 Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease

26 [Facial paralysis of metastatic origin. Review of metastatic lesions of the temporal bone]

27 β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation

28 On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database

29 SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET

30 [A study of tumor markers in hepatocellular carcinoma]

31 Risk stratification and prognostication of renal cell carcinoma.

32 YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage

33 Novel design of NIR-triggered plasmonic nanodots capped mesoporous silica nanoparticles loaded with natural capsaicin to inhibition of metastasis of human papillary thyroid carcinoma B-CPAP cells in thyroid cancer chemo-photothermal therapy.

34 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

35 Immunohistochemical localization of nephrocalcin, a kidney-specific glycoprotein, to renal cell carcinoma.

36 Targeting hepatocellular carcinoma: Synthesis of new pyrazole-based derivatives, biological evaluation, DNA binding, and molecular modeling studies

37 Association of CTLA-4 tagging polymorphisms and haplotypes with hepatocellular carcinoma risk: A case-control study.

38 High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules.

39 Ambovex® as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial

40 Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

41 Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma

42 Intermediate stage hepatocellular carcinoma: a summary review

43 Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve

44 Post-translational modifiers of liver kinase B1/serine/threonine kinase 11 in hepatocellular carcinoma

45 Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

46 Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

47 Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

48 Weighing the benefits of hepatocellular carcinoma surveillance against potential harms

49 Selecting patients with hepatocellular carcinoma for liver transplantation: incorporating tumor biology criteria

50 Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

51 Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein

52 Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)

53 Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer

54 Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance

55 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

56 Editorial: charting the future of hepatocellular carcinoma publications

57 Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt

58 Pretreatment neutrophil–lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma

59 Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma

60 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

61 Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions

62 Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma

63 Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

64 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

65 Hepatocellular carcinoma: early-stage management challenges

66 Screening for hepatocellular carcinoma: patient selection and perspectives

67 Open-label phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L

68 Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

69 A single institution report of 19 hepatocellular carcinoma patients with bile duct tumor thrombus

70 Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge

71 Pediatric hepatocellular carcinoma: challenges and solutions

72 Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients

73 Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration

74 Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

75 GPC-3 in hepatocellular carcinoma: current perspectives

76 Minimally invasive image-guided therapies for hepatocellular carcinoma

77 Hepatocellular carcinoma: a review

78 Does alpha-fetoprotein contribute to the mortality and morbidity of human hepatocellular carcinoma? A commentary

79 Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma

80 Transarterial radioembolization for hepatocellular carcinoma: a review

81 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

82 Hepatocellular carcinoma in elderly patients: challenges and solutions

83 Fibrolamellar hepatocellular carcinoma: current clinical perspectives

84 Role of endoscopic ultrasound in diagnosis and management of hepatocellular carcinoma

85 Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma

86 Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

87 Whither α-FP in the diagnosis of hepatocellular carcinoma?

88 The androgen receptor as an emerging target in hepatocellular carcinoma

89 Emerging role of Hpo signaling and YAP in hepatocellular carcinoma

90 Hapten-enhanced overall survival time in advanced hepatocellular carcinoma by ultro-minimum incision personalized intratumoral chemoimmunotherapy

91 Hepatocellular carcinoma ablation and possible immunity in the age of nanosecond pulsed electric fields

92 Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib

93 c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma

94 A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma

95 Emerging role of Toll-like receptor 4 in hepatocellular carcinoma

96 Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors

97 Welcome to Journal of Hepatocellular Carcinoma

98 Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy

99 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

100 Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

101 Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models

Keyword Connections

Journals

Research Groups

Bibliographies